Columbia Asset Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $294K | Buy |
5,333
+5
| +0.1% | +$271 | 0.06% | 141 |
|
|
2025
Q4 | $261K | Sell |
5,328
-795
| -13% | -$37.1K | 0.05% | 149 |
|
|
2025
Q3 | $264K | Buy |
6,123
+606
| +11% | +$23.7K | 0.05% | 147 |
|
|
2025
Q2 | $212K | Sell |
5,517
-894
| -14% | -$34.2K | 0.04% | 166 |
|
|
2025
Q1 | $248K | Sell |
6,411
-474
| -7% | -$17.4K | 0.05% | 177 |
|
|
2024
Q4 | $233K | Sell |
6,885
-2,245
| -25% | -$80.8K | 0.04% | 186 |
|
|
2024
Q3 | $373K | Buy |
9,130
+5
| +0.1% | +$205 | 0.07% | 145 |
|
|
2024
Q2 | $351K | Buy |
9,125
+795
| +10% | +$33.4K | 0.07% | 142 |
|
|
2024
Q1 | $309K | Hold |
8,330
| – | – | 0.06% | 145 |
|
|
2023
Q4 | $309K | Sell |
8,330
-1,630
| -16% | -$58.5K | 0.06% | 145 |
|
|
2023
Q3 | $361K | Buy |
9,960
+300
| +3% | +$10.6K | 0.08% | 131 |
|
|
2023
Q2 | $344K | Buy |
9,660
+360
| +4% | +$12.9K | 0.07% | 135 |
|
|
2023
Q1 | $331K | Buy |
9,300
+1,625
| +21% | +$56.9K | 0.07% | 132 |
|
|
2022
Q4 | $270K | Buy |
7,675
+2,335
| +44% | +$77.8K | 0.07% | 142 |
|
|
2022
Q3 | $157K | Sell |
5,340
-797
| -13% | -$30.2K | 0.04% | 162 |
|
|
2022
Q2 | $334K | Buy |
+6,137
| New | +$339K | 0.08% | 134 |
|
|
2021
Q4 | $430K | Sell |
7,810
-679
| -8% | -$35.3K | 0.09% | 135 |
|
|
2021
Q3 | $405K | Sell |
8,489
-228
| -3% | -$11.5K | 0.09% | 135 |
|
|
2021
Q2 | $434K | Sell |
8,717
-1,521
| -15% | -$73.1K | 0.1% | 132 |
|
|
2021
Q1 | $457K | Sell |
10,238
-2,735
| -21% | -$124K | 0.08% | 128 |
|
|
2020
Q4 | $597K | Buy |
12,973
+459
| +4% | +$21.1K | 0.12% | 114 |
|
|
2020
Q3 | $589K | Sell |
12,514
-579
| -4% | -$29K | 0.13% | 101 |
|
|
2020
Q2 | $668K | Buy |
13,093
+1,660
| +15% | +$85.2K | 0.16% | 95 |
|
|
2020
Q1 | $542K | Sell |
11,433
-780
| -6% | -$41.6K | 0.13% | 96 |
|
|
2019
Q4 | $7.17K | Hold |
12,213
| – | – | 0.17% | 96 |
|
|
2019
Q3 | $652K | Buy |
12,213
+5
| +0% | +$257 | 0.17% | 96 |
|
|
2019
Q2 | $611K | Sell |
12,208
-1,880
| -13% | -$94.3K | 0.16% | 104 |
|
|
2019
Q1 | $736K | Buy |
14,088
+1,904
| +16% | +$95.1K | 0.2% | 92 |
|
|
2018
Q4 | $582K | Buy |
12,184
+80
| +0.7% | +$3.94K | 0.18% | 97 |
|
|
2018
Q3 | $608K | Sell |
12,104
-1,000
| -8% | -$50.8K | 0.16% | 103 |
|
|
2018
Q2 | $660K | Hold |
13,104
| – | – | 0.19% | 99 |
|
|
2018
Q1 | $640K | Buy |
13,104
+600
| +5% | +$27.9K | 0.19% | 108 |
|
|
2017
Q4 | $554K | Sell |
12,504
-5,068
| -29% | -$234K | 0.16% | 116 |
|
|
2017
Q3 | $892K | Buy |
17,572
+820
| +5% | +$41.6K | 0.27% | 82 |
|
|
2017
Q2 | $902K | Buy |
16,752
+3,284
| +24% | +$175K | 0.29% | 79 |
|
|
2017
Q1 | $709K | Buy |
13,468
+1,560
| +13% | +$79.1K | 0.24% | 94 |
|
|
2016
Q4 | $573K | Sell |
11,908
-906
| -7% | -$44.8K | 0.19% | 105 |
|
|
2016
Q3 | $691K | Buy |
12,814
+2,380
| +23% | +$130K | 0.24% | 91 |
|
|
2016
Q2 | $565K | Sell |
10,434
-860
| -8% | -$45.3K | 0.2% | 104 |
|
|
2016
Q1 | $572K | Sell |
11,294
-272
| -2% | -$13.5K | 0.21% | 98 |
|
|
2015
Q4 | $583K | Buy |
11,566
+1,204
| +12% | +$61.4K | 0.23% | 98 |
|
|
2015
Q3 | $498K | Sell |
10,362
-1,834
| -15% | -$95.5K | 0.2% | 106 |
|
|
2015
Q2 | $634K | Buy |
12,196
+54
| +0.4% | +$3.04K | 0.24% | 104 |
|
|
2015
Q1 | $700K | Buy |
12,142
+2,096
| +21% | +$120K | 0.26% | 106 |
|
|
2014
Q4 | $537K | Buy |
10,046
+2,024
| +25% | +$113K | 0.21% | 117 |
|
|
2014
Q3 | $461K | Sell |
8,022
-72
| -0.9% | -$4.41K | 0.19% | 115 |
|
|
2014
Q2 | $541K | Buy |
8,094
+628
| +8% | +$42.5K | 0.22% | 107 |
|
|
2014
Q1 | $499K | Buy |
7,466
+304
| +4% | +$20.6K | 0.22% | 105 |
|
|
2013
Q4 | $478K | Buy |
+7,162
| New | +$464K | 0.21% | 105 |
|
Other funds holding GSK
JEST
Columbia Asset Management's GSK Position: Q1 2026 in Review
Columbia Asset Management increased its GSK (GSK) stake by 0.09% in Q1 2026, buying an estimated $271 and bringing the position to 5,333 shares worth $294K. The position accounts for 0.06% of the portfolio, ranked #141.
Columbia Asset Management first reported a position in GSK in Q4 2013 and has held it in 49 quarters since. The position peaked at $902K in Q2 2017. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Columbia Asset Management held 5,333 shares of GSK worth $294K as of Q1 2026.
- Columbia Asset Management bought 5 GSK shares in Q1 2026, an estimated $271.
- GSK made up 0.06% of Columbia Asset Management's portfolio in Q1 2026, its #141 holding.
- Columbia Asset Management first reported a position in GSK in Q4 2013 and has held it in 49 quarters since.
- Columbia Asset Management's GSK position peaked at $902K in Q2 2017.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Columbia Asset Management's 13F filing for Q1 2026, filed 21 Apr 2026.